膝、髋关节置换术对类风湿关节炎患者生存状况的影响

注册号:

Registration number:

ChiCTR2200060657 

最近更新日期:

Date of Last Refreshed on:

2023-03-26 14:23:30 

注册时间:

Date of Registration:

2022-06-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

膝、髋关节置换术对类风湿关节炎患者生存状况的影响

Public title:

Survival benefits of knee and hip arthroplasty in patients with rheumatoid arthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

膝、髋关节置换术对类风湿性关节炎患者生存状况的影响-一项基于人群的对列研究

Scientific title:

Survival benefits of knee and hip arthroplasty in patients with rheumatoid arthritis: a general population-based cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李辉 

研究负责人:

雷光华 

Applicant:

Hui Li 

Study leader:

Guanghua lei 

申请注册联系人电话:

Applicant telephone:

+86 13755089280

研究负责人电话:

Study leader's
telephone:

+86 13808429640

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lihui1988@csu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

lei_guanghua@csu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市开福区湘雅路87号

研究负责人通讯地址:

湖南省长沙市开福区湘雅路87号

Applicant address:

87 Xiangya Road, Changsha, Hunan, China

Study leader's address:

87 Xiangya Road, Changsha, Hunan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅医院

Applicant's institution:

Xiangya Hospital, Central South University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018091077

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湘雅医院医学伦理委员会

Name of the ethic committee:

The medical ethical committee at Xiangya Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2018-09-28 00:00:00

伦理委员会联系人:

肖佩君

Contact Name of the ethic committee:

Peijun Xiao

伦理委员会联系地址:

湖南省长沙市开福区湘雅路87号

Contact Address of the ethic committee:

87 Xiangya Road, Changsha, Hunan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学湘雅医院

Primary sponsor:

Xiangya Hospital, Central South University

研究实施负责(组长)单位地址:

湖南省长沙市开福区湘雅路87号

Primary sponsor's address:

87 Xiangya Road, Changsha, Hunan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

国家老年疾病临床研究中心项目

Source(s) of funding:

the Project Program of National Clinical Research Center for Geriatric Disorders

研究疾病:

类风湿性关节炎  

Target disease:

Rheumatoid arthritis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

研究膝关节置换术(KA)或髋关节置换术(HA)对类风湿关节炎患者(RA)全因死亡率以及心血管疾病(CVD)和静脉血管血管症(VTE)的关系。  

Objectives of Study:

We aimed to examine the relation of knee arthroplasty (KA) or hip arthroplasty (HA) to all-cause mortality as well as cardiovascular disease (CVD) and venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

无完整数据。

Exclusion criteria:

With no complete data.

研究实施时间:

Study execute time:

From 2022-06-13 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-13 00:00:00 To 2022-06-24 00:00:00

干预措施:

Interventions:

研究实施地点:

Countries of recruitment and research settings:

国家:

英国

省(直辖市):

市(区县):

 

Country:

United Kingdom

Province:

N/A

City:

单位(医院):

单位级别:

全科医生诊所 

Institution
hospital:

N/A

Level of the institution:

General practitioners

测量指标:

Outcomes:

指标中文名:

全因死亡率

指标类型:

主要指标

Outcome:

All-cause mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心血管疾病

指标类型:

次要指标

Outcome:

Cardiovascular disease

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

静脉血栓

指标类型:

次要指标

Outcome:

Venous thromboembolism

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不需随机。

Randomization Procedure (please state who generates the random number sequence and by what method):

Not available.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

不需盲法。

Blinding:

N/A

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

/(请阅读网站首页注册指南共享原始数据的方式内容)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

这些信息由全科医生收集,作为他们日常处置病人的一部分,这些信息被确定并集成到一个中央数据库,用于研究目的。诊断和测试过程用Read代码记录。通过使用编码药物字典(Multilex),初级保健医生写的处方自动记录在数据库中作为药物代码。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The information is collected by general practitioners as part of their routine patient care, which is deidentified and integrated into a central database for research purposes. Diagnoses and test procedures are recorded with Read codes. Prescriptions written by primary care physicians are recorded automatically in the database as Drug codes, with the use of a coded drug dictionary (Multilex).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-06-06 14:47:58